Objective
This study evaluated the presence and the levels of antibodies reactive to SARS-CoV-2 S1 and S2 subunits (S1 + S2), and nucleocapsid protein.

Study design
The levels of SARS-CoV-2 S1 + S2- and nucleocapsid-reactive SIgM/IgM, IgG and SIgA/IgA were measured in human milk samples from 41 women during the COVID-19 pandemic (2020-HM) and from 16 women 2 years prior to the outbreak (2018-HM).

Results
SARS-CoV-2 S1 + S2-reactive SIgA/IgA, SIgM/IgM and IgG were detected in 97.6%, 68.3% and 58.5% in human milk whereas nucleocapsid-reactive antibodies were detected in 56.4%, 87.2% and 46.2%, respectively. S1 + S2-reactive IgG was higher in milk from women that had symptoms of viral respiratory infection(s) during the last year than in milk from women without symptom. S1 + S2- and nucleocapsid-reactive IgG were higher in the 2020-HM group compared to the 2018-HM group.

Conclusions
The presence of SARS-CoV-2-reactive antibodies in human milk could provide passive immunity to breastfed infants and protect them against COVID-19 diseases.

Introduction
SARS-CoV-2 is the novel coronavirus discovered in 2019 (2019-nCoV) that is responsible for the severe acute respiratory syndrome (SARS) pandemic. The coronavirus disease 2019 (COVID-19) was first observed in China. SARS-CoV-2 is responsible for pandemic-level infections globally, including the United States [1]. To induce COVID-19, the spike 1 (S1) subunit attaches to angiotensin-converting enzyme-2 (ACE-2) receptors on the cellular surface of the human respiratory tract [2]. After binding to ACE-2, the spike 2 (S2) subunit fuses the viral particle to the host cell membrane and releases its RNA into the cell, initiating viral replication [3]. High concentrations of viral copies induce host cell lysis and the spread of infectious particles. During the infection, the immune response is activated to produce antibodies by plasma cells (activated B cells) specific to spike proteins (or other viral structural proteins) from SARS-CoV-2. Antibodies specific to S1 or S2 could neutralize and block the attachment and fusion of SARS-CoV-2 to the host cell, before its replication within the lungs and other tissue, including the gastrointestinal tract [4]. Cleavage of the spike protein is an essential step for SARS infection [5]. Antibodies that bind to the spike protein interfere with this cleavage, inhibiting the fusion and the entry of SARS-CoV-2 into the host cell. Therefore, neutralizing antibodies play an important role in viral clearance. The production of these antibodies specific to S1 or S2 could help to protect against future COVID-19 infection.
Infection by or exposure to SARS-CoV-2 could result in the production of secretory IgA (SIgA), IgA, secretory IgM (SIgM)/IgM and IgG antibodies specific to SARS-CoV-2 in human milk. A recent study found that milk from a woman diagnosed positive for COVID-19 (SARS-CoV-2 RNA was initially detected in nasopharyngeal but not in serum or breast milk samples) was positive for SARS-CoV-2-specific IgG and negative for IgM on day 8 and day 24 after admission [6], but the antigen used for their detection was not reported. The exposure of SARS-CoV (previous human coronavirus causing an endemic disease in 2003, in China) could also produce antibodies cross-reactive to SARS-CoV-2 that may be protective against COVID-19, as recent studies have demonstrated a genetic similarity between multiple proteins [7]. Among 45 epitopes on SARS-CoV-2 and SARS-CoV, the nucleocapsid has 22 identical epitopes, S1 has three identical epitopes and S2 has 22 identical epitopes [2]. Antibody reactive to S protein of SARS-CoV-2 could provide some protection for the infant from COVID-19 infection, but no evidence has been demonstrated at this moment.

The Center for Disease Control and Prevention recommends that pregnant women are vaccinated with inactivated influenza virus (flu shot) and tetanus-reduced-dose diphtheria and acellular pertussis (Tdap) during the late second or third trimester (27–36 weeks of gestation) to maximize protection against these infectious diseases in infants [8, 9]. Vaccine-derived IgG antibodies are transferred to the fetus via the placenta providing passive immunity against these pathogens [10, 11]. Pathogen-specific antibodies in human milk can also be generated during an infection or after exposure to pathogenic microbes [12]. Our previous study demonstrated the survival of influenza A-specific SIgA/IgA, SIgM/IgM and IgG from human milk in the gastrointestinal tract of preterm infants suggests possible protection against influenza diseases [13]. Vaccination could also modulate the adaptive immune responses by generating nonspecific antibodies, which may improve protection against infectious illnesses [14]. Coronaviruses (CoVs) and influenza viruses (IAVs) share some pathological changes and clinical symptoms in patients after infection [15]. The ligand-binding site of CoV hemagglutinin-esterase (HE), influenza hemagglutinin-fusion-esterase (HEF) and a subset of CoV spike protein are adapted to recognize 9-O-acetyl-sialoglycans to infect cells [16]. Therefore, human milk could possibly contain cross-reactive antibodies that neutralize other coronaviruses or other viruses, including influenza viruses. This would be beneficial in terms of protecting newborns from a variety of viral pathogens.

In this study, we examined the presence and levels of SIgM/IgM, IgG and SIgA/IgA reactive to both SARS-CoV-2 S1 and S2 subunits (S1 + S2) and nucleocapsid protein in human milk collected during the COVID-19 pandemic and 2 years prior to the outbreak. We also compared these antibody levels between vaccinated and unvaccinated mothers as well as between women that had symptoms of viral respiratory infection(s) during the year and women without symptoms. Human milk SARS-CoV-2-reactive antibodies could be used as a potential oral antibody therapy to prevent COVID-19 disease, especially to susceptible individuals, including newborns and immunosuppressed patients.

Materials and methods

Study design and participants

The first group of human milk samples (2020-HM) was collected during the COVID-19 pandemic (from 03/02/20 to 03/04/20). These donors were not asked about their COVID-19 status, specific symptoms related to SARS-CoV-2, or if they were exposed to COVID-19 positive individuals. A survey was completed by each mother in the 2020-HM group to determine their vaccination status during pregnancy and if they had symptoms of viral respiratory infection during the last year. No mothers were sick (with any type of infection) during the milk collection. The screening survey did include an opportunity to share general viral symptoms, many of which were COVID-19 related [15]. The second group of human milk samples (2018-HM) was collected from 16 mothers between 06/09/18 and 29/11/18, before the COVID-19 pandemic. These human milk samples were used as a control group. All women (from both the 2020-HM and 2018-HM groups) were living in the United States (see demographic description in Tables 1 and 2) and were approved donors through Mothers Milk Cooperative (Boulder City, NV). Written consents to use their milk for research were obtained from those mothers.

Milk collection was approved by the institutional review board (IRB00012424) of Medolac Laboratories. The criteria pre-established for inclusion are passing blood tests (negative tests for HIV, HTLV, hepatitis B or C and syphilis), living in the USA, completing a health questionnaire, and no use of specific medications. Mothers, who were smokers or drug users were excluded.

Human milk collection

Human milk samples (150–250 mL) were collected at home with clean electric breast pumps into sterile plastic containers and stored immediately at −20 °C in deep freezers. The breast was cleaned with a wet washcloth (no soap or alcohol) before pumping. Milk samples were frozen and transported in insulated boxes to Medolac Laboratories, where they were kept frozen and stored at −30 °C in an industrial freezer until the ELISA measurements.
gestation). Few women (n = 26) during the milk collection. These symptoms were self-reported and did not answer the question on the symptoms of viral infection during the last year.

| Demographics | Vaccinated (n = 26) | Unvaccinated (n = 15) |
|--------------|---------------------|----------------------|
| Postpartum time | 5 ± 3 (2–10) | 5 ± 3 (2–11) |
| Infant gender, n | 11 males:15 females | 6 males:9 females |
| Influenza vaccine, n | 11 | – |
| Tdap vaccine, n | 8 | – |
| Influenza and Tdap, n | 7 | – |
| Viral symptoms, n | 10 | 5 |
| No symptoms, n | 9 | 4 |

aData are mean ± SD.

Women were vaccinated with tetanus-reduced-dose diphtheria and acellular pertussis (Tdap) vaccine and/or inactivated influenza virus (flu) vaccine between the second and third trimester (27–36 weeks of gestation).

Women had symptoms of viral respiratory infection (cold, fever, respiratory infection, sinus infection, nasal congestion, headaches, sore throat and/or flu-like symptoms) during the last year but no infection during the milk collection. These symptoms were self-reported and could be bacterial, allergies or faulty memory. Few women (n = 13) did not answer the question on the symptoms of viral infection during the last year.

| Demographics | 2020-HM (n = 41) | 2018-HM (n = 16) |
|--------------|------------------|------------------|
| Postpartum time, months | 5 ± 3 (2–1) | 5 ± 3 (2–10) |
| Infant gender, n | 17 males:24 females | 8 males:8 females |
| No vaccine, n (%) | 15 (36.6) | 10 (63.0) |
| Influenza vaccine, n (%) | 11 (26.8) | 3 (18.8) |
| Tdap vaccine, n (%) | 8 (19.5) | 2 (12.5) |
| Influenza and Tdap, n (%) | 7 (17.1) | 1 (6.2) |

aData are mean ± SD.

Women were vaccinated with tetanus-reduced-dose diphtheria and acellular pertussis (Tdap) vaccine and/or inactivated influenza virus (flu) vaccine between the second and third trimester (27–36 weeks of gestation).

SARS-CoV-2 S1 + S2- and nucleocapsid-reactive antibodies

The levels of SARS-CoV-2 S1 + S2 and nucleocapsid-reactive SIgM/IgM, IgG, and SIgA/IgA were determined using ELISAs that were adapted from our previous publications [13, 17–19]. ELISAs were recorded with a microplate reader (SpectraMax iD5, Molecular Devices, Sunnyvale, CA). Raw human milk samples (n = 41) were rapidly thawed at 37 °C in a water bath and centrifuged at 1301 × g for 20 min at 4 °C. After removing the fat layer, the supernatant was collected, separated into aliquots and stored at −30 °C until analyzed. Clear flat-bottom microplates (Nunc MaxiSorp, Thermo Fisher Scientific, Rochester, NY) were coated with 100 μL of recombinant SARS-CoV-2 (2019-nCoV) S1 + S2 or nucleocapsid (Sino Biological US Inc., Wayne, PA) at 1 μg/mL in 1x phosphate-buffered saline pH 7.4 (PBS, Gibco, Grand Island, NY). Microwells were incubated overnight at 4 °C. After incubation, plates were washed three times using PBS with 0.05% Tween-20 detergent (PBST) (Thermo Fisher Scientific, Rochester, NY) and 200 μL of blocking buffer (PBST with 3% of bovine serum albumin fraction V (Roche Diagnostic GmbH, Mannheim, Germany) was added in all wells for 1 h at room temperature. Standards were prepared using human milk supernatant with the highest optical density (OD) value for each ELISA. Six different standards were used due to the difference of OD values between the different isotypes (SIgM/IgM vs. IgG vs. SIgA/IgA) and the antigens (S1 + S2 vs. nucleocapsid) (Fig. S1). The standards were selected based on the preliminary data of 12 human milk samples diluted at 10× for IgG and SIgM/IgM and at 50× for SIgA/IgA. The levels of SARS-CoV-2 S1 + S2- and nucleocapsid-reactive antibodies were interpolated from the standard curves generated from the human milk supernatants with the assigned quantity expressed in ELISA units/mL (U/mL) (10×-diluted human milk sample = 200 arbitrary U/mL for IgG and IgM, 50×-diluted milk sample = 62.5 arbitrary U/mL for SIgA/IgA). The standard curves were prepared using the dilution series of the human milk supernatants in blocking buffer that covered a range from 2.5× (800 U/mL) to 160× (12.5 U/mL) for SIgM/IgM, from 2.5× (800 U/mL) to 80× (25 U/mL) for IgG and from 15.6× (200 U/mL) to 500× (6.25 U/mL) for SIgA/IgA. Supernatants of human milk samples were diluted 10× for SIgM/IgM and IgG, and 50× for SIgA/IgA with a blocking buffer. Before each step (addition of 100 μL standards/samples and secondary antibodies at 1 μg/mL), washing and incubation for 1 h at room temperature were performed. The detection SARS-CoV-2 S1 + S2- and nucleocapsid-reactive antibodies were goat anti-human IgM mu-chain HRP for SIgM/IgM, goat anti-human gamma-chain HRP for IgG and goat anti-human alpha-chain HRP for SIgA/IgA (Abcam, Cambridge, MA).

Inactivation of SARS-CoV-2 S1 + S2 and nucleocapsid-reactive antibodies

Diluted (10× for SIgM/IgM and IgG and 50× for SIgA/IgA) milk supernatants were either heated at 100 °C for 30 min using an Isotemp (Fisher Scientific, Chino, CA) or non-heated (stored in ice) for 30 min, in triplicate for each condition. SARS-CoV-2 S1 + S2- and nucleocapsid-reactive SIgM/IgM, IgG, and SIgA/IgA were measured with ELISAs as previously described above.
Statistical analysis

Mann–Whitney test for unpaired sample comparisons of SARS-CoV-2 S1 + S2 and nucleocapsid-reactive antibodies in human milk for vaccinated vs. unvaccinated, influenza-vaccinated vs. non-influenza-vaccinated, Tdap-vaccinated vs. non-Tdap-vaccinated, viral symptoms vs. no symptom and 2020-HM group vs. 2018-HM group were applied using GraphPad Prism (version 8). Friedman test (paired samples) followed by Dunn’s test (correction for multiple comparisons) was used to compare the levels of isotypes (SIgM/IgM, IgG and SIgA/IgA) of SARS-CoV-2- S1 + S2- and nucleocapsid-reactive antibodies in human milk. Linear regression models were used to determine a correlation between SARS-CoV-2 S1 + S2- and nucleocapsid-reactive antibodies. Pearson correlation coefficients (r) were determined when p < 0.1. The sample size of vaccinated mothers (n = 26) and unvaccinated mothers (n = 15) was selected based on our previous study [13].

Results

Maternal demographics

The maternal demographic details of vaccinated donors and unvaccinated donors in 2020-HM group are presented in Table 1. Maternal demographic details of women in 2020-HM group and women in 2018-HM group are described in Table 2. Postpartum time and the ratio of male to female infants were similar between vaccinated and unvaccinated mothers in the 2020-HM and 2018-HM groups. The number of women who had symptoms of viral infection during the last year and the number of women without infection were similar between vaccinated and unvaccinated women.

Presence and levels of SARS-CoV-2 S1 + S2- and nucleocapsid-reactive antibodies in human milk

The presence of SARS-CoV-2 S1 + S2-reactive SIgM/IgM, IgG, and SIgA/IgA was detected in 68.3% (Fig. 1a), 58.5% (Fig. 1b), 97.6% (Fig. 1c) in human milk samples, respectively. The presence of SARS-CoV-2 nucleocapsid-reactive SIgM/IgM, IgG and SIgA/IgA was detected in 87.2% (Fig. 1d), 46.2% (Fig. 1e) and 56.4% (Fig. 1f) in human milk samples, respectively. The detection of SIgM/IgM reactive to nucleocapsid in human milk was 1.2-fold higher than SIgM/IgM reactive to S1 + S2. The detection of IgG reactive to nucleocapsid was comparable to the IgG reactive to S1 + S2. The detection of SIgA/IgA reactive to nucleocapsid in human milk was 1.7-fold lower compared to SIgA/IgA reactive to S1 + S2.

The level of SARS-CoV-2 S1 + S2-reactive SIgA/IgA in human milk was higher than SIgM/IgM and IgG (p < 0.001), which were comparable (Fig. 2a). The level of SARS-CoV-2 nucleocapsid-reactive SIgM/IgM was higher than IgG (p < 0.001) and SIgA/IgA (p = 0.038), whereas SIgA/IgA was higher than IgG (p = 0.038, Fig. 2b).

The levels of SARS-CoV-2 S1 + S2- and nucleocapsid-reactive IgG were 4.3- (p = 0.013) and 2.7-fold (p = 0.041)
higher in 2020-HM group (milk collected during COVID-19 pandemic) compared to the 2018-HM group (milk collected 2 years ago COVID-19, control group), respectively (Fig. 3b, e). The levels of SIgA/IgA and SIgM/IgM reactive to S1 + S2 (Fig. 3a, c) and nucleocapsid (Fig. 3d, f) were comparable between the 2020-HM and 2018-HM groups.

SARS-CoV-2 S1 + S2-reactive IgG from vaccinated women was 2.9-fold higher than unvaccinated women ($p = 0.004$, Fig. 2c). S1 + S2-reactive IgG from influenza-vaccinated women was higher than non-influenza-vaccinated women ($p = 0.031$, Fig. 2d), but did not differ between Tdap-vaccinated and non-Tdap-vaccinated women (data not shown). S1 + S2-reactive SlgA/IgA or SlgM/IgM were comparable between vaccinated and unvaccinated women.
women (Fig. S3A and Fig. S3D), between influenza-vaccinated and non-influenza-vaccinated (Fig. S3B, S3E), and between Tdap-vaccinated and non-Tdap-vaccinated (data not shown). The levels of antibodies reactive to nucleocapsid were not affected by the vaccination during pregnancy.

Fig. 3 The levels of antibodies reactive to SARS-CoV-2 S1 and S2 subunits (S1 + S2) and nucleocapsid in human milk collected during the COVID-19 pandemic (2020-HM) and 2 years prior this pandemic (2018-HM). Levels of S1 + S2-reactive a secretory IgM (SIgM/IgM), b IgG and c secretory IgA (SIgA/IgA) in 2020-HM and 2018-HM. Levels of nucleocapsid-reactive d SIgM/IgM, e IgG and f SIgA/IgA in 2020-HM and 2018-HM. Values are mean ± SD, n = 41 for 2020-HM and n = 16 for 2018-HM. Asterisks show statistically significant differences between variables (*p < 0.05) using the Mann–Whitney test (unpaired nonparametric test). ns Not statistically significant.

Fig. 4 Regression linear between antibodies reactive to SARS-CoV-2 S1 and S2 subunits (S1 + S2) and nucleocapsid in human milk collected during the COVID-19 pandemic in 41 women.

a Positive correlation of S1 + S2-reactive secretory IgA (SIgA/IgA) and S1 + S2-reactive secretory IgM (SIgM/IgM). b Positive correlation between S1 + S2-reactive SIgA/IgA and nucleocapsid-reactive SIgA/IgA. c Positive correlation between nucleocapsid-reactive SIgA/IgA and SIgM/IgM. d Positive correlation between nucleocapsid-reactive SIgM/IgM and S1 + S2-reactive SIgM/IgM. Pearson correlation coefficients (r) were determined when p < 0.1.
Effect of viral respiratory infection on SARS-CoV-2 S1 + S2-reactive antibodies in human milk

SARS-CoV-2 S1 + S2-reactive IgG detected in milk from women that had symptoms of a viral respiratory infection (self-reporting diagnosis) during the last year was 3.5-fold higher than women without symptoms in the last year ($p = 0.049$, Fig. 2e). No difference was found between mothers with symptoms of viral infection and mothers without symptoms of viral infection for SIgM/IgM or SIgA/IgA with symptoms of viral infection and mothers without symptoms of viral infection for SIgM/IgM or SIgA/IgA (Fig. S3C, Fig. S3F). The levels of antibodies reactive to nucleocapsid were not affected by viral respiratory infection.

Standard curves and inactivation of SARS-CoV-2 S1 + S2- and nucleocapsid-reactive antibodies

The dose responses for the standard curves SARS-CoV-2 S1 + S2- and nucleocapsid-reactive SlgM/IgM, IgG, SlgA/IgA using serial dilutions (2-fold) of milk supernatants are illustrated in Fig. S4A–S4F. The selection of each standard (supernatant human milk with high OD values) for each ELISA is illustrated in Fig. S1. Binding capacity of SARS-CoV-2 S1 + S2- and nucleocapsid-reactive SlgM/IgM, IgG and SlgA/IgA from human milk was completely inactivated after heat-treatment at 100 °C for 30 min (Fig. S5A–S5B).

Discussion

The first confirmed case of COVID-19 in the United States was formally diagnosed in January 2020. Confirmed cases rapidly increased to 100 cases on 01/03/20, 9317 cases on 10/03/20, 9317 cases on 18/03/20 and 105,217 cases on 27/03/20 [1]. Antibodies specific or reactive to SARS-CoV-2 in human milk might provide some protection for the infant against COVID-19. However, the levels of SARS-CoV-2 S1 + S2- and nucleocapsid-reactive IgG, SlgM/IgM and SlgA/IgA in human milk are still unknown. In this study, SARS-CoV-2 S1 + S2- and nucleocapsid-reactive SlgM/IgM, IgG and SlgA/IgA antibodies were detected in a high proportion of human milk samples collected from 30/02/20 to 09/04/20. Some mothers may have been exposed or infected with SARS-CoV-2, as asymptomatic infections are common [20]. However, it is possible that the detected antibodies were not only due to SARS-CoV-2 infection, but also due to cross-reactivity with other coronaviruses or other virus families [21–23]. A recent study reported that SARS-CoV-2-specific CD4+ T cells (from convalescent blood) were detected in 40–60% of unexposed individuals to COVID-19, suggesting a high degree of cross-reactive and preexisting immunity to SARS-CoV-2 in some, but not all, individuals [23]. Moreover, patients infected with SARS-CoV produced antibodies reactive to HCoV-OC43 [22] whereas patients infected with HCoV-OC43 secreted antibodies reactive to SARS-CoV [21]. The presence of cross-reactive antibodies between SARS-CoV and HCoV-OC43 may be possible due to the homology between epitopes on the nucleocapsid (S1 and S2 were not evaluated) [21, 22]. Moreover, the detected SlgM/IgM and SlgA/IgA reactive to SARS-CoV-2 S1 + S2 and nucleocapsid could be related to the polyreactive nature of human milk SlgA and SlgM [24–26]. Polyreactive antibodies with low affinity possess an antigen-binding pocket that is more flexible (the ability to bind to several different ligands) than monoreactive antibodies with high affinity [27]. Polyreactive antibodies can accommodate their conformation and recognize various antigens by using different interacting residues [28]. Therefore, polyreactive SlgA and SlgM in human milk could neutralize a higher range of pathogens [24–26], especially considering the high rate of detected antibodies. The levels of antibodies reactive to SARS-CoV-2 S1 + S2 were investigated due to the spike proteins’ role in inducing infection and its lower genetic similarity with other coronaviruses. The levels of antibodies reactive to nucleocapsid were compared to those with S1 + S2- reactive antibodies. The neutralizing capacity and potential role of human milk antibodies reactive to SARS-CoV-2 S1 + S2 and nucleocapsid in providing passive immunity to infants remains to be seen.

There is only one prior study [6] describing the presence of SARS-CoV-2-specific antibodies in human milk. SARS-CoV-2-specific IgG (on day 8 and 24) was detected in milk from a woman positive for SARS-CoV-2, but the level and specificity of IgG to SARS-CoV-2 were not reported [6]. Another report [29] qualitatively observed the presence of antibodies specific to SARS-CoV (unreported antigen or epitopes) in maternal serum and breast milk collected at 131 days after illness onset in a patient infected with SARS-CoV.

SlgA is the most prevalent isotype in human milk [18, 19]. We found a similar distribution for SARS-CoV-2 S1 + S2-reactive antibodies in mother’s milk. Among 41 healthy mothers, a higher number of mothers had S1 + S2-reactive SlgA/IgA (97.6%) compared to IgG (58.5%) or SlgM/IgM (68.3%) reactive to S1 + S2. The level of SARS-CoV-2 S1 + S2-reactive SlgA/IgA was higher than IgM and IgG reactive to S1 + S2. This is likely reflective of the decreasing prevalence of these antibody classes in human milk (SlgA/IgA > IgG = SlgM/IgM). The proportion of antibodies in human milk is ~80% total IgA (~73% SlgA/SlgA27% IgA), ~15% total IgM (SlgM + IgM) and ~5% IgG [18].

The detection and levels of nucleocapsid-reactive SlgM/IgM were higher than S1 + S2-reactive SlgM/IgM, which could be due to the high polyreactive and/or cross-reactive
capacity of SIgM to nucleocapsid [24–26]. The detection of IgG reactive to S1 + S2 was lower than IgG reactive to the nucleocapsid. This result could be due to the high cross-reactive capacity of IgG to the nucleocapsid. These observations are in agreement with the genetic similarity of nucleocapsid protein (22 identical epitopes), which is higher (over 90%) compared to S protein (76%, the number of identical epitopes was 3 for S1 and 20 for S2) between SARS-CoV-2 and SARS-CoV [2]. In contrast, the detected SIgA/IgA reactive to S1 + S2 was higher than the nucleocapsid likely due to a high polyreactive and/or cross-reactive capacity of SIgA/IgA to S1 + S2 [24–26]. This observation could be related to the structural similarity of S2 subunits between SARS-CoV-2 and SARS-CoV (or other coronaviruses) [2, 30]. Previous studies demonstrated that cross-reactive antibodies from convalescent blood to SARS-CoV-2 and other common coronaviruses [21–23]. Our future study will demonstrate the cross-reactive capacity of human milk antibodies to S1 + S2 between HCoV-OC43 and SARS-CoV-2 as well as their polyreactive capacity to both S1 and S2 (evaluated separately) from SARS-CoV-2. Therefore, the constant region of human milk antibodies may influence their reactivity to SARS-CoV-2 S1 + S2 and nucleocapsid.

SARS-CoV-2 S1 + S2-reactive IgG in milk from influenza-vaccinated women during pregnancy was higher than unvaccinated or non-influenza-vaccinated women. Similarly, SARS-CoV-2 S1 + S2-reactive IgG in milk from women that had viral respiratory infection symptoms during the last year was higher than women without infection. These results suggest that SARS-CoV-2 S1 + S2-reactive IgG in human milk was more associated with the activation of immune responses related to viral diseases or influenza vaccine than SIgM/IgM or SIgA/IgA. This association could be due to the systemic response that a respiratory infection or vaccination induces as IgG is the most abundant in bloodstream whereas SIgA/IgA is more produced in the mucosal secretions (related to enteric pathogens or oral immunization). IgG, which is mostly produced at the end of an infection, is highly effective at opsonization (facilitating phagocytosis) and activating the complement system, and is often associated with immunity and resistance [31]. Another explanation of these results could be related to the cross-reactive capacity of human milk IgG. IgG produced during the pandemic H1N1 infection were broadly cross-reactive against epitopes in the head domain of multiple influenza strains [32]. There are several strains of CoVs (HCoV-NL63, HCoV-HKU1 and HCoV-OC43) and IAVs (H1N1, H5N1, H7N9 and H3N2) that cause seasonal cold and/or respiratory diseases. CoVs and IAVs share some pathological changes and clinical symptoms in patients after infection [15]. The HCoV-OC43 spike and HCoV-HKU1 spike proteins share some functionality (receptor attachment and membrane fusion) with influenza A/B hemagglutinin [16]. Human milk IgG might be cross-reactive to CoVs and other viruses, including IAVs. However, more studies are needed to confirm the cross-reactive capacity of human milk antibodies to neutralize SARS-CoV-2 and IAVs.

Among other benefits, mother’s milk provides protection against viral respiratory infection, partially due to the transfer of maternal viral pathogen-specific antibodies to the infant. The lacteal lymphatic capillary located exclusively in the intestinal villi of the small intestine is responsible for absorbing lipids, immune surveillance and removal of interstitial fluid. This capillary may absorb and transport human milk antibodies to the respiratory system as its bed connects the gastrointestinal system with the lymphatic and circulatory systems. It could be a possible mechanism for the protection against neonatal respiratory tract infections in infants [33]. Exclusive breastfeeding during the first 6 months of life significantly decreases infant febrile respiratory illnesses [34]. Studies on human milk antibodies specific to respiratory viruses have focused on associations between maternal vaccination during pregnancy and human milk IgG, IgM and IgA levels to influenza viruses [35]. This study demonstrated another benefit of influenza-vaccination on maternal antibodies specific to respiratory viruses in human milk. Infants of influenza-vaccinated mothers who were exclusively breastfed in the first 6 months of life had significantly fewer respiratory illness with fever episodes [36]. Jarvinen et al. recently observed that unlike IgG antibodies, influenza A virus-specific IgA antibody levels in human milk were mostly discordant compared to maternal serum [37]. This observation could be related to the polyreactive properties of SIgA in human milk compared with IgA in serum.

The first few cases of COVID-19 in the United States were reported during January 2020, but the kinetics of producing strong SARS-CoV-2-specific antibody responses requires at least two weeks. Thus, some women may have been exposed to SARS-CoV-2 before the milk collection (from 30/02/20 to 04/09/20) and their human milk may contain antibodies specific to SARS-CoV-2. A limitation of this study was the absence of information on whether the mothers were previously infected with or exposed to SARS-CoV-2. We did not detect viral RNA from SARS-CoV-2 in all human milk samples using real-time RT-qPCR (data not shown), which suggests the mothers were likely not infected with SARS-CoV-2 during the milk collection.

**Conclusion**

In summary, this study revealed that antibodies reactive to SARS-CoV-2 S1 + S2 and nucleocapsid were detected in a high proportion in human milk. The constant region of human milk antibodies may influence their reactivity to
SARS-CoV-2 S1 + S2 and nucleocapsid. The S1gA/IgA and S1gM/IgM responses appeared to be nonspecific to SARS-CoV-2 S1 + S2 and nucleocapsid and therefore SARS-CoV-2-specific IgA and IgM were not measurable with the current assays. Their high relative abundance and proportion in mother’s milk samples are due to their cross-reactive and polyreactive properties of human milk secretory antibodies. The IgG responses seem distinct between unexposed and exposed women’s samples. However, some overlap in the IgG response was observed between unexposed and exposed women. The relevance of the unexposed women who have SARS-CoV-2-specific IgG response detected in the same range as the exposed women should be evaluated using neutralization assays. The presence of SARS-CoV-2-reactive antibodies in human milk could provide passive immunization to the breastfed infants. There is currently no effective oral antibody therapy for COVID-19 infection. Human milk antibodies with high polyreactive and cross-reactive properties against SARS-CoV-2 and other coronaviruses could be useful to neutralize and protect against future coronavirus pandemics, especially in vulnerable populations. The purification of antibodies reactive to SARS-CoV-2 from human milk is needed to evaluate their neutralizing capacity against SARS-CoV-2 using in vitro and in vivo studies.

Acknowledgements We thank all study participants for their valuable contributions.

Funding The authors (VDM, DMD, GBM and ED) disclosed receipt of the financial support from Medolac Laboratories A Public Benefit Corporation for the conduct of the study.

Author contributions VDM conceptualized and designed the study, carried out the analyses and the statistical analysis, drafted the manuscript and approved the final paper as submitted. VDM have primary responsibility for the final content. DMD and GBM carried out some ELISA analyses. EM have obtained the funding acquisition of this study. DMD, GBM, DAS, AS, KMJ and EM provided suggestions for analyses and critically revised the paper and approved the final paper as submitted.

Compliance with ethical standards

Conflict of interest VDM, DMD, GBM and EM are employees at Medolac Laboratories. DAS is on the scientific advisory board for Medolac Laboratories. AS and KMJ have no conflict of interest to disclose.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

1. Johns Hopkins University & Medicine. COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU). 2020. https://coronavirus.jhu.edu/map.html.
2. Ahmed SF, Quadeer AA, McKay MR. Preliminary identification of potential vaccine targets for the COVID-19 coronavirus (SARS-CoV-2) based on SARS-CoV immunological studies. Viruses 2020;12:254.
3. Fu Y, Cheng Y, Wu Y. Understanding SARS-CoV-2-mediated inflammatory responses: from mechanisms to potential therapeutic tools. Virol Sin. 2020;35:266–71.
4. Sungnak W, Huang N, Bécavin C, Berg M, Queen R, Litvinukova M. et al. SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes. Nat Med. 2020;26:681–7.
5. Du L, He Y, Zhou Y, Liu S, Zheng BJ, Jiang S. The spike protein of SARS-CoV—a target for vaccine and therapeutic development. Nat Rev Microbiol. 2009;7:226–36.
6. Yu, Y., Xu, J., Li, Y., Hu, Y., & Li, B. Breast milk-fed infant of COVID-19 pneumonia mother: A case report. Research Square, Preprint. 2020. https://doi.org/10.21203/rs.3.rs-20792/v1.
7. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395:565–74.
8. Centers for Disease Control and Prevention (CDC). Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Tdap) in pregnant women and persons who have or anticipate having close contact with an infant aged <12 months—Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2011;60:1424–6.
9. Centers for Disease Control and Prevention (CDC). Vaccines during and after pregnancy. 2019. https://www.cdc.gov/vaccines/pregnancy/vacc-during-after.html.
10. Healy CM, Rench MA, Baker CJ. Importance of timing of maternal combined tetanus, diphtheria, and acellular pertussis (Tdap) immunization and protection of young infants. Clin Infect Dis. 2012;56:539–44.
11. Halperin BA, Morris A, Mackinnon-Cameron D, Mutch J, Langley JM, McNeil SA, et al. Kinetics of the antibody response to tetanus-diphtheria-acellular pertussis vaccine in women of childbearing age and postpartum women. Clin Infect Dis. 2019;53:885–92.
12. Raya BA, Srugo I, Kessel A, Peterman M, Bader D, Peri R, et al. The induction of breast milk pertussis specific antibodies following gestational tetanus–diptheria–acellular pertussis vaccination. Vaccine. 2014;32:5632–7.
13. Demers-Mathieu V, Huston RK, Markell AM, McCulley EA, Martin RL, Dallas DC. Antenatal influenza A-specific IgA, IgM, and IgG antibodies in mother’s own breast milk and donor breast milk, and gastric contents and stools from preterm infants. Nutrients. 2019;11:1567.
14. Aaby P, Kollmann TR, Benn CS. Nonspecific effects of neonatal and infant vaccination: public-health, immunological and conceptual challenges. Nat Immunol. 2014;15:895–9.
15. Jiang C, Yao X, Zhao Y, Wu J, Huang P, Pan C, et al. Comparative review of respiratory diseases caused by coronaviruses and influenza A viruses during epidemic season. Microb Infect. 2020;22:236–44.
16. Tortorici MA, Walls AC, Lang Y, Wang C, Li Z, Koerhuis D, et al. Structural basis for human coronavirus attachment to sialic acid receptors. Nat Struct Mol Biol. 2019;26:481–9.
17. Demers-Mathieu V, Underwood MA, Beverly RL, David DC. Survival of immunoglobulins from human milk to preterm infant gastric samples at 1, 2, and 3 h postprandial. Neonatology. 2018;114:242–50.
18. Demers-Mathieu V, Underwood MA, Beverly RL, Nielsen SD, Dallas DC. Comparison of human milk immunoglobulin survival during gastric digestion between preterm and term infants. *Nutrients*. 2018;10:631.

19. Demers-Mathieu V, Huston RK, Markell AM, McCulley EA, Martin RL, Spooner M, et al. Differences in maternal immunoglobulins within mother’s own breast milk and donor breast milk and across digestion in preterm infants. *Nutrients*. 2019;11:920.

20. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. *N Engl J Med*. 2020;382:1708–20.

21. Patrick DM, Petric M, Skowronski DM, Guasparini R, Booth TF, Krajden, et al. An outbreak of human coronavirus OC43 infection and serological cross-reactivity with SARS coronavirus. *Can J Infect Dis Med Microbiol*. 2006;17:330–6.

22. Chan KH, Chan JF, Tse H, Chen H, Lau CC, Cai JP, et al. Cross-reactive antibodies in convalescent SARS patients’ sera against the emerging novel human coronavirus EMC (2012) by both immunofluorescent and neutralizing antibody tests. *J Infect*. 2013;67:130–40.

23. Grifoni A, Weiskopf D, Ramirez SI, Mateus J, Dan JM, Moderbacher CR, et al. Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. *Cell*. 2020;181:1489–501.e15.

24. Taylor HP, Dimmock NJ. Mechanism of neutralization of influenza virus by secretory IgA is different from that of monomeric IgA or IgG. *J Exp Med*. 1985;161:198–209.

25. Stubbe H, Berdoz J, Kraehenbuhl JP, Cortés B. Polymeric IgA is superior to monomeric IgA and IgG carrying the same variable domain in preventing *Clostridium difficile* toxin A damaging of T84 monolayers. *J Immunol*. 2000;164:1952–60.

26. Cortés B. Recombinant secretory immunoglobulin A in passive immunotherapy: linking immunology and biotechnology. *Curr Pharm Biotechnol*. 2003;4:51–67.

27. Gunti S, Notkins AL. Polyreactive antibodies: function and quantification. *J infect Dis*. 2015;212:S42–6.

28. Mouquet H, Nussenzweig MC. Polyreactive antibodies in adaptive immune responses to viruses. *Cell Mol Life Sci*. 2012;69:1435–45.

29. Robertson CA, Lowther SA, Birch T, Tan C, Sorhage F, Stockman L, et al. SARS and pregnancy: a case report. *Emerg Infect Dis*. 2004;10:345.

30. Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. *Cell*. 2020;181:281–92.e6.

31. Janda A, Bowen A, Greenspan NS, Casadevall A. Ig constant region effects on variable region structure and function. *Front Microbiol*. 2016;7:22.

32. Wrammert J, Koutsonanos D, Li GM, Edupuganti S, Sui J, Morrissey M, et al. Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. *J Exp Med*. 2011;208:181–93.

33. Cifarelli V, Eichmann A. The intestinal lymphatic system: functions and metabolic implications. *Cell Mol Gastroenterol Hepatol*. 2019;7:503–13.

34. Frank NM, Lynch KF, Uusitalo U, Yang J, Lönnrot M, Virtanen SM, et al. The relationship between breastfeeding and reported respiratory and gastrointestinal infection rates in young children. *BMC Pediatr*. 2019;19:339.

35. Maertens K, De Schutter S, Braeckman T, Baerts L, Van Damme P, De Meester I, et al. Breastfeeding after maternal immunisation during pregnancy: providing immunological protection to the newborn: a review. *Vaccine*. 2014;32:1786–92.

36. Schlaudecker EP, Steinhoff MC, Omer SB, McNeal MM, Roy E, Arifeen SE, et al. IgA and neutralizing antibodies to influenza virus in human milk: a randomized trial of antenatal influenza immunization. *PLoS ONE*. 2013;8:e70867.

37. Jarvinen KM, Wang J, Seppo AE, Zand M. Novel multiplex assay for profiling influenza antibodies in breast milk and serum of mother-infant pairs. *F1000Res*. 2018;7:1822.